Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

DCanVAX

Financiado

Cerrado

A novel immuno-oncolytic virus-based dendritic cell therapeutic cancer vaccine

Following decades of development, therapeutic cancer vaccines are beginning to gain momentum in demonstrating therapeutic effects, and they represent a particularly promising approach. The aim of therapeutic cancer vaccines is to... ver más

31/07/2025

TUM-MED

Presupuesto desconocido

Líder del proyecto

KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIV... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-02-01

ERC-2023-POC: ERC PROOF OF CONCEPT GRANTS Objective:Objectives:The ERC Proof of Concept Grants aim at facilitating exploration of the commerci...

I+D

Cerrada hace 2 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

TUM-MED

Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

IMMUNO-TEX Overcoming resistance to immunotherapy: Immunostimulatory tu... 2M€ Cerrado

PeptiCrad Personalized oncolytic vaccines for cancer immunotherapy 2M€ Cerrado

PROCROP Professional cross priming for ovary and prostate cancer 8M€ Cerrado

EUIN2013-51221 PREPARACION DE PROPUESTA PARA HORIZONTE2020CUREMYELOMA 15K€ Cerrado

PID2019-109102RA-I00 NUEVAS ESTRATEGIAS PARA SUPERAR LAS LIMITACIONES DE LA TERAP... 145K€ Cerrado

TrojanDC Harnessing dendritic cell reprogramming for cancer immunothe... 2M€ Cerrado

Duración del proyecto: 17 meses Fecha Inicio: 2024-02-01
Fecha Fin: 2025-07-31

Líder del proyecto

KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIV... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Following decades of development, therapeutic cancer vaccines are beginning to gain momentum in demonstrating therapeutic effects, and they represent a particularly promising approach. The aim of therapeutic cancer vaccines is to stimulate immunity against tumor antigens, usually through the use of whole cells, peptides, or nucleic acids (i.e. mRNAs). Dendritic cell- (DC) based vaccines represent particularly interesting candidates for therapeutic cancer vaccine products due to their ability to cross-present antigens to T cells, thereby driving adaptive immune responses through induction of antigen-specific cytotoxic T lymphocytes. Despite the potential of DC-based cancer vaccines, several major limitations have hindered their success in clinical studies. These limitations include insufficient ex vivo maturation of DCs and challenges in selecting optimal tumor antigens to target. The aim of DCanVAX is to develop a novel oncolytic virus-based dendritic cell vaccine approach for systemic therapy of solid cancers. We propose that the use of a highly immuno-oncolytic virus as a mechanism to lyse tumor cells ex-vivo, will lead to the release of the entire tumor antigen library, as well as a cocktail of danger signals in response to the virus infection. By applying this highly immunogenic lysate to autologous DCs, an optimized and personalized DC vaccine can be generated. This method overcomes the major challenges that have been encountered by DC vaccine approaches in the clinic, by providing a potent mechanism of DC maturation and activation, while simultaneously exposing the DCs to the complete repertoire of tumor antigens that are specific to the patient, leading to potent and broad tumor-specific immune responses against the cancer. This approach can be developed for multiple solid cancer indications and combined with other immunotherapy approaches for potentially synergistic therapeutic effects.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores